Home Newsfeeds Compass Point Downgrades HarborOne Bancorp to Neutral, Announces $14 Price Target

Compass Point Downgrades HarborOne Bancorp to Neutral, Announces $14 Price Target

Compass Point analyst Laurie Havener downgrades HarborOne Bancorp (NASDAQ:HONE) from Buy to Neutral and announces $14 price target.

byBenzinga Newsdesk

October 20, 2022

1 minute read

Compass Point analyst Laurie Havener downgrades HarborOne Bancorp (NASDAQ:HONE) from Buy to Neutral and announces $14 price target.

Barclays Maintains Equal-Weight on Dun & Bradstreet Hldgs, Lowers Price Target to $17

By Benzinga Newsdesk

July 1, 7:14 AM

Barclays analyst Manav Patnaik maintains Dun & Bradstreet Hldgs (NYSE:DNB) with a Equal-Weight and lowers the price target from $18 to $17.

DNB

Check Out 3 Tech Stocks With Over 4% Dividend Yields From Wall Street’s Most Accurate Analysts

By Lisa Levin

September 29, 8:52 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

ADTN

Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock

By Lara Goldstein

March 14, 6:34 PM

FSD Pharma Inc. (NASDAQ: HUGE) has renewed a service agreement with shareholder intelligence services provider ShareIntel LLC to assist in ongoing

HUGE

FDA Lifts Clinical Hold On BioCryst’s BCX9930 Program For Rare Blood Disorder

By Vandana Singh

August 4, 12:11 PM

The FDA lifted a partial clinical hold on BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) BCX9930 program. The company will resume enrollment under revised protocols…

BCRX

Compass Point Downgrades HarborOne Bancorp to Neutral, Announces $14 Price Target

Related Posts

Barclays Maintains Equal-Weight on Dun & Bradstreet Hldgs, Lowers Price Target to $17

Check Out 3 Tech Stocks With Over 4% Dividend Yields From Wall Street’s Most Accurate Analysts

Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock

FDA Lifts Clinical Hold On BioCryst’s BCX9930 Program For Rare Blood Disorder